|Manufacturer:||Pacific Pharmaceuticals manufactures Famox.|
|Uses:||The uses of Famox include:|
2.Benign gastric ulcer
3.Hypersecretory conditions such as Zollinger-Ellison
4.Prevention of relapses of duodenal ulceration
5.Prevention of relapses of benign gastric ulcer
6.Symptomatic relief of gastroesophageal reflux disease.
7.Healing of oesophageal erosion or ulceration associated
with gastroesophageal reflux disease
8.Prevention of relapses of symptoms and erosions or
ulcerations associated with GERD.
Dosage and Administration
Initial Therapy: The recommended dose of famotidine is one 40mg tablet daily taken at night. Treatment should be given for four to eight weeks, but the duration of treatment may be shortened if endoscopy reveals that the ulcer has healed. In most cases of duodenal ulcer, healing occurs within four weeks on this regimen. In those patients whose ulcers have not healed completely after four weeks, treatment should be continued for a further four week period.
Maintenance Therapy: For the prevention of recurrence of duodenal ulceration, it is recommended that therapy with famotidine be continued with a dose of one 20mg tablet daily taken at night.
Benign Gastric Ulcer:
The recommended dose of famotidine is one 40mg tablet daily taken at night. Treatment should be given for 4-8 weeks, but the duration of treatment may be shortened if endoscopy reveals that the ulcer has healed.
Maintenance Therapy: For the prevention of recurrence of benign gastric ulcer, the recommended dosage is one 20mg tablet taken at night which may be given for up to one year.
Patients without prior antisecretory therapy should be started on a dose of 20mg every 6 hours. Dosage should be adjusted to individual patient needs and should continue for as long as indicated clinically. Doses up to 800mg daily have been used for up to one year without the development of significant adverse effects or tachyphylaxis. Patients who have been receiving another H2-antagonist may be switched directly to famotidine at a starting dose higher than that recommended for new cases; this starting dose will depend on the severity of the condition and the last dose of the H2-antagonist previously used.
Gastroesophageal Reflux Disease:
The recommended dosage for the symptomatic relief of gastroesophageal reflux disease is 20mg of famotidine twice daily.
For the treatment of oesophageal erosion or ulceration associated with GERD, the recommended dosage is 40mg of famotidine twice daily.
Maintenance Therapy: For the prevention of recurrence of symptoms and erosions or ulcerations associated with GERD the recommended dosage is 20mg of famotidine twice daily.
Dosage Adjustment for Patients with Severe Renal Insufficiency:
In adult patients with moderate (creatinine clearance <50mL/min) or severe (creatinine clearance <10mL/min) renal insufficiency, the elimination half-life of famotidine is increased. For patients with severe renal insufficiency it may exceed 20 hours, reaching approximately 24 hours in anuric patients. Since CNS adverse effects have been reported in patients with moderate and severe renal insufficiency, to avoid excess accumulation of the medicine in patients with moderate and severe renal insufficiency, the dose of famotidine may be reduced to half the dose or the dosing interval may be prolonged to 36-48 hours as indicated by the patient's clinical response